References on Cancer Research Using ALZET^® Osmotic Pumps

R0249 Tamamura,H., Tsutsumi,H., Fujii,N. The chemokine receptor CXCR4 as a therapeutic target for several diseases. MINI-REVIEWS IN MEDICINAL CHEMISTRY 2006; 6(-9-):989-995. >>> TN14003, 4F-benzoyl-; SC; Mice; mice (SCID); ; Cancer (breast carcinoma); immunology; peptides; Review, see p. 990, ref. #22; p. 992, red. # 56.

R0248 Tsutsumi,H., Tamamura,H., Fujii,N. Inhibitors of the chemokine receptor CXCR4: Chemotherapy of AIDS, metastatic cancer, leukemia and rheumatoid arthritis. Letters in Drug Design&Discovery 2007; 4(-1-):20-26. >>> TN14003, 4F-benzoyl-; SC; Mice; Mice (SCID); ; Cancer (breast carcinoma); immunology; peptides; CXCR4 antagonist; review, see p. 21, 23.

R0243 Sachdev,D., Yee,D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. MOLECULAR CANCER THERAPEUTICS 2007; 6(-1-):1-12. >>> Insulin-like growth factor binding protein-1, recomb. human; BSA; SC; Mice; 2 weeks; Controls received mp w/ vehicle; comparison of SC injections vs. mp; half-life (p. 4) "very short;" cancer (breast); peptides; animal info (athymic); review, see pg. 4-5; "IGFBP-1 had to be administered via osmotic pumps because of its very short half-life and it was ineffective on a twice-daily schedule in vivo." (p. 4).

R0238 Boeckle,S., Wagner,E. Optimizing targeted gene delivery: Chemical modification of viral vectors and synthesis of artificial virus vector systems. AAPS Journal 2006; 8(-4-):E731-E742. >>> Virus, synthetic RNA; Intratumoral; Mice (nude); ; Cancer (glioblastoma); "Control animals within 30 days after tumor implantation, all treated animals survived for >1 year and were completely cured." (p. E738); gene therapy.

P9202 Tejeda,M., Gaal,D., Hullan,L., Csuka,O., Schwab,R., Szokoloczi,O., Keri,G.Y. Continuous Administration of the Somatostatin Structural Derivative /TT-232/ by Subcutaneously Implanted Osmotic Pump Improves the Efficacy and Potency of Antitumor Therapy in Different Mouse and Human Tumor Models. Anticancer Research 2008; 28(-5A-):2769-2774. >>> TT-232; Water, distilled; acetic acid; sodium acetate; mannitol; SC; IV (jugular); Mice; 2001; 2002; 7; 14; 28 days; Comparison of IP and SC injections vs. SC and IV mp; pumps replaced after 2 weeks; PE-10 tubing used; "The frequent and long-lasting repetition of TT-232 injection enhanced its therapeutic efficacy; however, serial injection causes significant stress to animals and adequate precautions are required. To this end, an Alzet osmotic minipump inserted s.c. and i.v. was used." pg 2773; "The results obtained from this study suggest that TT-232 is a good candidate for delivery by continuous (infusion) therapy; cancer.

P9198 Rennel,E.S., Hamdollah-Zadeh,M.A., Wheatley,E.R., Magnussen,A., Schueler,Y., Kelly,S.P., Finucane,C., Ellison,D., Cebe-Suarez,S., Ballmer-Hofer,K., Mather,S., Stewart,L., Bates,D.O., Harper,S.J. Recombinant human VEGF165b protein is an effective anti-cancer agent in mice. European Journal of Cancer 2008; 44(-13-):1883-1894. >>> Vascular endothelial growth factor-165-b, recomb.; NaCl, sterile; SC; Mice; 28 days; No stress (see pg. 1888); half-life (p. 1893) 25 min in mice, 13.8-72 min in rats; cancer (colon); post op. care (Temgesic); animal info (C57/Bl6, 720 g.); silk sutures used; "no adverse effects were observed with this infusion of VEGF165b" pg. 1888; compound is an anti angiogenic isoform of VEGF.

P9170 Eichelbaum,E.J., Sun,Y., Alli,A.A., Gower,WR Jr, Vesely,D.L. Cardiac and kidney hormones cure up to 86% of human small-cell lung cancers in mice. European Journal of Clinical Investigation 2008; 38(-8-):562-570. >>> Natriuretic peptide, long acting; atrial natriuretic peptide; vessel dilator peptide; kaliuretic peptide; urodilatin; Saline; SC; Mice (nude); 1007D; 4 weeks; Controls received mp w/ vehicle; cancer (small cell lung); peptides; animal info (nu/nu, athymic); urodilatin is a kidney hormone.

P9137 Barkan,D., Kleinman,H., Simmons,J.L., Asmussen,H., Kamaraju,A.K., Hoenorhoff,M.J., Liu,Z.Y., Costes,S.V., Cho,E.H., Lockett,S., Khanna,C., Chambers,A.F., Green,J.E. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Research 2008; 68(-15-):6241-6250. >>> ML-7; DMSO; Mice; 2004; 1 week; Controls received mp w/ vehicle; enzyme inhibitor (myosin light chain kinase, MLCK); cancer (breast); animal info (4-6 wks old, female, BALB/c, nu/nu).

P9117 Kasaoka,T., Nishiyama,H., Okada,M., Nakajima,M. Matrix metalloproteinase inhibitor, MMI270 (CGS27023A) inhibited hematogenic metastasis of B16 melanoma cells in both experimental and spontaneous metastasis models. CLINICAL&EXPERIMENTAL METASTASIS 2008; 25(-7-):827-834. >>> MMI270; DMSO; PEG 300; SC; Mice; 2004; 2004; 14; 21 days; Comparison of SC injections vs. mp; enzyme inhibitor (matrix metalloproteinase); cancer (melanoma); animal info (7 wks old, BDF1, male, lymphadrectomy; 50% DMSO used; 50% PEG 300.

P9114 Iwasa,T., Okamoto,I., Suzuki,M., Nakahara,T., Yamanaka,K., Hatashita,E., Yamada,Y., Fukuoka,M., Ono,K., Nakagawa,K. Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non-Small Cell Lung Cancer Cell Lines. Clinical Cancer Research 2008; 14(-20-):6496-6504. >>> YM155; Saline; Mice (nude); 1003D; 7 days; Controls received mp w/ vehicle; cancer (lung); animal info (BALB/c, athymic, 6 wks old, female); YM155 is a small inhibitor of surviving expression.

P9094 van der,Pluijm G., Que,I., Sijmons,B., Buijs,J.T., Lowik,C.W., Wetterwald,A., Thalmann,G.N., Papapoulos,S.E., Cecchini,M.G. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res. 2005/9/1; 65(-17-):7682-7690. >>> Olpadronate; NaCl; water; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; cancer; animal (female, BALB/c, nu/nu); olpadronate is a bisphosphonate.

P9084 Zhang,J.J., Zafrullah,M., Yang,X., Yin,X.L., Zhang,Z.G., Fuks,Z., Kolesnick,R. Downregulation of KSR1 in pancreatic cancer xenografts by antisense oligonucleotide correlates with tumor drug uptake. CANCER BIOLOGY&THERAPY 2008; 7(-9-):1492-1497. >>> Oligonucleotide, antisense; PBS; SC; Mice; 5 days; Controls received mp w/ vehicle; antisense (KSR1); cancer (pancreatic).

P9077 Ye,L., Lewis-Russell,J.M., Sanders,A.J., Kynaston,H., Jiang,W.G. HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS 2008; 26(-2-):190-197. >>> Hepatocyte growth factor, recomb. human; NK4, recomb. human; SC; Mice (nude); 2004; 4 weeks; Cancer (prostate); animal info (athymic, male, CD-1, 4-6 wks old).

P9057 Masunaga,S., Sakurai,Y., Nagata,K., Suzuki,M., Maruhashi,A., Kinashi,Y., Nagasawa,H., Uto,Y., Hori,H., Ono,K. The usefulness of a continuous administration of tirapazamine combined with reduced dose-rate irradiation using gamma-rays or reactor thermal neutrons. British Journal of Radiology 2006; 79(-948-):991-998. >>> Uridine, bromodeoxy-; tirapazamine; Saline; SC; Mice; 2001D; 5 days; 24 hours; Tissue perfusion (tumor); comparison of IP injections vs. mp; cancer; animal info (8-11 wks old, female, syngenic C3H, He); tirapazamine, also known as TP2, is a lead compound as a bioreactive hypoxic cytotoxin; labing of P cells; cancer.

P8992 Dreau,D., Foster,M., Hogg,M., Culberson,C., Nunes,P., Wuthier,R.E. Inhibitory effects of fusarochromanone on melanoma growth. Anti-cancer Drugs 2007; 18(-8-):897-904. >>> Fusarochromanone; PBS; IP; Mice (SCID); 2004; 17 days; Controls received mp w/ vehicle; comparison of IP injections vs. mp; pumps replaced after 7 days; cancer (melanoma); animal info (female, BALB/c SCID, 20 g.).

P8991 Liu,X.D., Fridman,J.S., Wang,Q., Caulder,E., Yang,G.J., Covington,M., Liu,C., Marando,C., Zhuo,J.C., Li,Y.L., Yao,W., Vaddi,K., Newton,R.C., Scherle,P.A., Friedman,S.M. Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. CANCER BIOLOGY&THERAPY 2006; 5(-6-):648-656. >>> INCB003619; DMSO; SC; Mice (nude); 6, 28 days; Controls received mp w/ vehicle; functionality of mp verified by plasma INCB003619 levels; dose-response (fig. 5); enzyme inhibitor (ADAM protease); cancer (breast); animal info (female, athymic, CD-1, nu/nu, 7-8 wks old).

P8983 Ott,T., Jokwitz,M., Lenhard,D., Romualdi,A., Dombrowski,F., Ittrich,C., Schwarz,M., Willecke,K. Ablation of gap junctional communication in hepatocytes of transgenic mice does not lead to disrupted cellular homeostasis or increased spontaneous tumourigenesis. European Journal of Cell Biology 2006; 85(-8-):717-728. >>> Uridine, bromodeoxy-; Mice; 1003D; 3 days; Cancer (breast, liver); animal info (male, C57BL/6-129sv, wt, Cx32 -/-, Cx26, FL/FL, Cx26 FL/FL:AlfpCre); "BrdU was applied by osmotic pumps over a period of 3 days to avoid diurnal variation in proliferation." (p. 720).

P8982 Masunaga,S.I., Nagasawa,H., Sakurai,Y., Uto,Y., Hori,H., Nagata,K., Suzuki,M., Maruhashi,A., Kinashi,Y., Ono,K. The usefulness of mild temperature hyperthermia combined with a newly developed hypoxia-oriented 10B conjugate compound, TX-2100, for boron neutron capture therapy. International Journal of Hyperthermia 2006; 22(-4-):287-299. >>> Uridine, bromodeoxy; Saline, physiological; SC; Mice; 5 days; Cancer (squamous cell carcinoma); animal info (female, C3H/He, 8-11 wks old).

P8928 Tejeda,M., Gaal,D., Hullan,L., Csuka,O., Schwab,R., Szokolocz,O., Keri,G. A comparison of the tumor growth inhibitory effect of intermittent and continuous administration of the somatostatin structural derivative TT-232 in various human tumor models. Anticancer Research 2006; 26(-4B-):3011-3015. >>> TT-232; Water, distilled; acetic acid; sodium acetate; mannitol; SC; Mice (SCID); 2002; 14, 28 days; Comparison of IP, SC injections vs. SC mp; stability verified by 3 weeks at 37 degree Celsius by HPLC analysis for agent + degradation products; cancer (epidermoid carcinoma, breast carcinoma); peptides; animal info (female, SCID, 22-24 g.); somatostate structural derivative; "The comparative experiments (injection and infusion) confirmed that continuous treatments and long-term administration were associated with the best treatment responses" (p. 3014); "Continuous infusion administration of TT-232 significantly inhibited the growth of the tumor when compared with intraperitoneal (ip) and subcutaneous (sc) intermittent injection treatments." (p. 3011).

P8927 Chen,J.H., Wu,C.W., Kao,H.L., Chang,H.M., Li,A.F.Y., Liu,T.Y., Chi,C.W. Effects of COX-2 inhibitor on growth of human gastric cancer cells and its relation to hepatocyte growth factor. Cancer Letters 2006; 239(-2-):263-270. >>> Hepatocyte growth factor; IP; Mice (SCID); 28 days; Controls received sham operation; pumps replaced after 14 days; cancer (gastric); peptides; post op. care (streptomycin, penicillin); animal info (male, SCID, 6-8 wks old, 20-25 g.).

P8926 Cui,G.L., Takaishi,S., Ai,W.D., Betz,K.S., Florholmen,J., Koh,T.J., Houghton,J., Pritchard,D.M., Wang,T.C. Gastrin-induced apoptosis contributes to carcinogenesis in the stomach. LABORATORY INVESTIGATION 2006; 86(-10-):1037-1051. >>> Gastrin-17; SC; Mice; 8 weeks; Controls received mp w/ PBS; functionality of mp verified by serum gastrin levels; long-term study; pumps replaced; cancer (gastric); peptides; animal info (male, GAS-KO, 2 months old).

P8925 Ye,L., Lewis-Russell,J.M., Davies,G., Sanders,A.J., Kynaston,H., Jiang,W.G. Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells. INTERNATIONAL JOURNAL OF ONCOLOGY 2007; 30(-2-):521-529. >>> Hepatocyte growth factor, recomb. human; SC; Mice (nude); 2004; 4 weeks; Controls received mp w/ BSA buffer; cancer (prostate); peptides; animal info (female, athymic, nude, CD-1, 4-6 wks old); HGF antagonist.

P8846 Dikmen,Z.G., Gellert,G.C., Dogan,P., Yoon,H., Lee,Y.B., Ahn,C.H., Shay,J.W. In vivo and in vitro effects of a HIF-1alpha inhibitor, RX-0047. Journal of Cellular Biochemistry 2008; 104(-3-):985-994. >>> RX-0047; oligonucleotide, phosphorothioate antisense; SC; IP; Mice (nude); 1002; 14 days; Controls received no treatment; comparison of IP injections vs. mp; antisense (HIF-1a); cancer (lung, prostate); animal info (Nu/Nu).

P8835 Rogers,A.B., Theve,E.J., Feng,Y., Fry,R.C., Taghizadeh,K., Clapp,K.M., Boussahmain,C., Cormier,K.S., Fox,J.G. Hepatocellular carcinoma associated with liver-gender disruption in male mice. Cancer Research 2007; 67(-24-):11536-11546. >>> Interferon-gamma, recomb. murine; SC; Mice; 7 days; Controls received mp w/ vehicle; cancer (tumorigenic hepatitis, liver); peptides; animal info (male, female, A/JCr).

P8817 Dings,R.P.M., Van Laar,E.S., Webber,J., Zhang,Y., Griffin,R.J., Waters,S.J., MacDonald,J.R., Mayo,K.H. Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Letters 2008; 265(-2-):270-280. >>> Anginex; anginex topomimetic 0118; SC; Mice (nude); 28 days; Cancer (ovarian carcinoma); animal info (female, athymic nu/nu, 5-6 wks old); antiangiogenic.

P8815 Jin,H.K., Yang,R.H., Zheng,Z., Romero,M., Ross,J., Bou-Reslan,H., Carano,R.A.D., Kasman,I., Mai,E., Young,J., Zha,J.P., Zhang,Z.M., Ross,S., Schwall,R., Colbern,G., Merchant,M. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Research 2008; 68(-11-):4360-4368. >>> Hepatocyte growth factor, human; Dextran sulfate; IP; Mice (nude); 1002; ; Controls received mp w/ vehicle; functionality of mp verified by human HGF serum levels; long-term study; pumps replaced every 12 to 14 days; cancer (pancreatic); peptides; animal info (female, nu/nu).

P8811 Nagano,S., Perentes,J.Y., Jain,R.K., Boucher,Y. Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Research 2008; 68(-10-):3795-3802. >>> Doxycycline; SC; Mice (SCID); 3 days; Controls received mp w/ saline; cancer (mammary carcinoma); animal info (SCID).

P8791 Song,P.F., Sekhon,H.S., Fu,X.W., Maier,M., Jia,Y.B., Duan,J., Proskosil,B.J., Gravett,C., Lindstrom,J., Mark,G.P., Saha,S., Spindel,E.R. Activated cholinergic signaling provides a target in squamous cell lung carcinoma. Cancer Research 2008; 68(-12-):4693-4700. >>> Darifenacin; DMSO; PBS; SC; Mice (nude); 2004; 4 weeks; Controls received mp w/ vehicle; cancer (lung carcinoma); animal info (male, nu/nu); 50% DMSO; M3 mAChR antagonist.

P8780 Albertsson,P., Lennernaes,B., Norrby,K. Dose effects of continuous vinblastine chemotherapy on mammalian angiogenesis mediated by VEGF-A. Acta Oncologica 2008; 47(-2-):293-300. >>> Vinblastine sulfate; Saline, physiological; SC; Rat; 2001; 2ML1; 6-10 days; Controls received mp w/ vehicle; dose-response (fig. 2); no stress (see pg. 296); cancer; animal info (male, Sprague Dawley, 217-219g.).

P8729 Masunaga,S., Takahashi,A., Ohnishi,K., Nagata,K., Suzuki,M., Kashino,G., Kinashi,Y., Ohnishi,T., Ono,K. Dependency of repair of radiation-induced damage on p53 status and efficient inhibition of the repair with wortmannin treatment in vivo, with reference to the effect on intratumor quiescent cell population. Oncology Reports 2007; 18(-6-):1589-1596. >>> Uridine, bromodeoxy-; Saline; SC; Mice (nude); 2001; 7 days; Tissue perfusion (tumor); cancer; animal info (Balb/cA, nude); labeling of tumor cells.

P8712 Vasvari,G.P., Dyckhoff,G., Kashfi,F., Lemke,B., Lohr,J., Helmke,B.M., Schirrmacher,V., Plinkert,P.K., Beckhove,P., Herold-Mende,C.C. Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo. International Journal of Cancer 2007; 121(-8-):1697-1704. >>> Cisplatin; IP; Mice (SCID); 1002; 4 weeks; Controls received no treatment; pumps replaced after 2 weeks; no stress (see pg. 1699); cancer (head/neck squamous cell carcinoma); animal info (female, NOD/SCID, 6-8 wks old, 15-25g).

P8704 Tummalapalli,P., Spomar,D., Gondi,C.S., Olivero,W.C., Gujrati,M., Dinh,D.H., Rao,J.S. RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. INTERNATIONAL JOURNAL OF ONCOLOGY 2007; 31(-5-):1039-1050. >>> RNA, small interfering; Mice (nude); 3-4 weeks; Controls received no treatment; cancer (meningioma); animal info (athymic, nude); siRNA plasmid vectors targeting cathepsin B and matrix metalloproteinase MMP9.

P8699 Chen,J., Lu,Q., Balthasar,J.P. Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 2007; 34(-6-):829-847. >>> Topotecan HCl; KH2PO4 buffer; IP; Mice; 1003D; 1007D; 7 days; 24, 72 hours; Controls received mp w/ vehicle; dose-response (fig. 4); comparison of IV, IP injections vs. mp; enzyme inhibitor (topoisomerase); cancer (ovarian); animal info (male, Swiss Webster, 20-30g).

P8698 Badn,W., Visse,E., Darabi,A., Smith,K.E., Salford,L.G., Siesjoe,P. Postimmunization with IFN-gamma-secreting glioma cells combined with the inducible nitric oxide synthase inhibitor mercaptoethylguanidine prolongs survival of rats with intracerebral tumors. Journal of Immunology 2007; 179(-6-):4231-4238. >>> L-NIL; Saline; IP; Rat; 2001; 7, 14 days; Controls received mp w/ PBS; pumps replaced after 7 days and 3 non-delivery days; enzyme inhibitor (iNOS); cancer (glioma); animal info (Fischer 344, 8-10 wks old); L-N6-(1-imminoethyl)-lysine.

P8677 King,T., Vardanyan,A., Majuta,L., Melemedjian,O., Nagle,R., Cress,A.E., Vanderah,T.W., Lai,J., Porreca,F. Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer. Pain 2007; 132(-1-2-):154-168. >>> Morphine; naloxone; Saline; SC; Mice; 1007D; 7 days; Controls received mp w/ vehicle; dose-response (p. 157, 159); no stress (see pg. 155); cancer (bone); multiple pumps per animal (2); animal info (20-25g, male, adult, C3H/HeJ); pain.

P8637 Fichera,A., Little,N., Dougherty,U., Mustafi,R., Cerda,S., Li,Y.C., Delgado,J., Arora,A., Campbell,L.K., Joseph,L., Hart,J., Noffsinger,A., Bissonnette,M. A vitamin D analogue inhibits colonic carcinogenesis in the AOM/DSS model. Journal of Surgical Research 2007; 142(-2-):239-245. >>> RO-26-2198; DMSO; PEG; SC; Mice; 28 days; Controls received mp w/ vehicle; cancer (colitis-associated colon); animal info (male, A/J); 50% DMSO.

P8636 Shao,T.C., Li,H., Ittmann,M., Cunningham,G.R. Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer. Journal of Urology 2007; 178(-4-):1521-1527. >>> Dutasteride; DMSO; PEG 400; SC; Mice (transgenic); 2004; 4, 8 weeks; Controls received mp w/ vehicle; comparison of oral admin. vs. mp; long-term study; pumps replaced after 4 weeks; no stress (see pg. 1522); enzyme inhibitor (5a-reductase); cancer (prostate); animal info (male, LPB-Tag, tg, wt, 6-7 and 10-11 wks old); 40% DMSO; "Dutasteride greatly decreased prostate tumor growth... without significant negative effects." p. 1526.

P8565 Veiseh,M., Gabikian,P., Bahrami,S.B., Veiseh,O., Zhang,M., Hackman,R.C., Ravanpay,A.C., Stroud,M.R., Kusuma,Y., Hansen,S.J., Kwok,D., Munoz,N.M., Sze,R.W., Grady,W.M., Greenberg,N.M., Ellenbogen,R.G., Olson,J.M. Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res. 2007/7/15; 67(-14-):6882-6888. >>> Chlorotoxin; SC; Mice; ; Controls received mp w/ vehicle; cancer; peptides; scorpion venom (toxin).

P8564 van der Bilt,J.D.W., Soeters,M.E., Duyverman,A.M.M.J., Nijkamp,M.W., Witteveen,P.O., van Diest,P.J., Kranenburg,O., Rinkes,I.H.M.B. Perinecrotic hypoxia contributes to ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases. American Journal of Pathology 2007; 170(-4-):1379-1388. >>> Arginine, L-; SC; Mice; 2001; 5 days; Controls received mp w/ vehicle; cancer (colorectal); animal info (male, BALB/c, 10-12 weeks old); nitric oxide donor.

P8542 Sakai,T., Balasubramanian,K., Maiti,S., Haider,J.B., Schroit,A.J. Plasmin-cleaved beta-2-glycoprotein 1 is an inhibitor of angiogenesis. American Journal of Pathology 2007; 171(-5-):1659-1669. >>> Glycoprotein 1, B-2-; glycoprotein 1, nicked B-2-; SC; IP; Mice; 2002; 28 days; Controls received mp w/ HSA; cancer (prostate adenocarcinoma); peptides; multiple pumps per animal (2); animal info (male, C57BL/6, 6 weeks old); B2GP1 is also known as apolipoprotein H; mp implanted IP on day 1, SC on day 14, implanted pumps not removed.

P8528 Neal,Z.C., Sondel,P.M., Bates,M.K., Gillies,S.D., Herweijer,H. Flt3-L gene therapy enhances immunocytokine-mediated antitumor effects and induces long-term memory. CANCER IMMUNOLOGY IMMUNOTHERAPY 2007; 56(-11-):1765-1774. >>> Interleukin-2, recomb. human; SC; Mice; 2001; 4 days; Controls received mp w/ no treatment; cancer (neuroblastoma); peptides; animal info (female, A/J, ICR, 6-8 weeks old).

P8520 Kumar,R., Knick,V.B., Rudolph,S.K., Johnson,J.H., Crosby,R.M., Crouthamel,M.C., Hopper,T.M., Miller,C.G., Harrington,L.E., Onori,J.A., Mullin,R.J., Gilmer,T.M., Truesdale,A.T., Epperly,A.H., Boloor,A., Stafford,J.A., Luttrell,D.K., Cheung,M. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. MOLECULAR CANCER THERAPEUTICS 2007; 6(-7-):2012-2021. >>> GW771806; SC; Mice (nude); mice (SCID); 2001; 5,6,21 days; Controls received mp w/ vehicle; dose-response (fig. 4); comparison of oral gavage vs. mp; cancer (colon); animal info (female, Swiss nu/nu, 8-12 weeks old); VEGFR inhibitor; "Continuous infusion of VEGFR inhibitor is more effective in controlling tumor growth and angiogenesis than p.o bolus dosing." (p. 2018).

P8514 Ishikawa,M., Kitayama,J., Yamauchi,T., Kadowaki,T., Maki,T., Miyato,H., Yamashita,H., Nagawa,H. Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. CANCER SCIENCE 2007; 98(-7-):1120-1127. >>> Adiponectin, recomb. mouse; PBS; IP; Mice (nude); 2004; 14 days; Controls received mp w/ vehicle; comparison of intratumoral injections vs. mp; no stress (see pg. 1124); cancer (gastric); peptides; animal info (female, BALB/c, nude, 5 weeks old); "Continuous adiponectin infusion into the peritoneal cavity caused significant antitumor effects." (p. 1126); "The intraperitoneal infusion did not cause apparent side effects with no significant change of total weight." (p. 1124).

P8512 Huang,Y., Chen,X., Dikov,M.M., Novitskiy,S.V., Mosse,C.A., Yang,L., Carbone,D.P. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 2007; 110(-2-):624-. >>> Vascular endothelial growth factor 165, recomb. human; vascular endothelial growth factor, receptor-2 selective; vascular endothelial growth factor, receptor-1 selective; Mice; 2004; 28 days; Controls received mp w/ PBS; cancer; peptides; animal info (female, Balb/c, 6-8 weeks old); angiogenesis; hematology.

P8510 Djalilian,H.R., Caicedo,E., Lessan,K., Grami,V., Le,C.T., Spellman,S.R., Pambuccian,S., Hall,W.A., Low,W.C., Ondrey,F.G. Efficacy of an osmotic pump delivered, GM-CSF-based tumor vaccine in the treatment of upper aerodigestive squamous cell carcinoma in rats. CANCER IMMUNOLOGY IMMUNOTHERAPY 2007; 56(-8-):1207-1214. >>> Granulocyte-macrophage colony stimulating factor, murine; interleukin-12; PBS; SC; Rat; 28 days; Controls received mp w/ vehicle; dose-response (fig 1); no stress (see pg. 1209); cancer (upper aerodigestive tract carcinoma); peptides; animal info (Fisher 344, 125-150 g); good methods; "This latter method (mp) has several advantages. First, the use of minipumps obviates the cumbersome need to transfect tumor cells and completely characterize their cytokine repertoires. Second, it allows for independent and rigorous control over the kinetics of administration of cytokine and antigen dosages. Third, it may generate les controversy than those techniques requiring "gene therapy" IRB approval." (p. 1213)..

P8504 Wilkinson,R.W., Odedra,R., Heaton,S.P., Wedge,S.R., Keen,N.J., Crafter,C., Foster,J.R., Brady,M.C., Bigley,A., Brown,E., Byth,K.F., Barrass,N.C., Mundt,K.E., Foote,K.M., Heron,N.M., Jung,F.H., Mortlock,A.A., Boyle,F.T., Green,S. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clinical Cancer Research 2007; 13(-12-):3682-3688. >>> AZD1152; SC; Mice; 2001D; 48 hours; Controls received mp w/ vehicle; dose-response (p. 3684); comparison of IV or IP injections; enzyme inhibitor (aurora B kinase); cancer; xenograft; animal info (male, 8-12 weeks old, Swiss athymic).

P8498 Tsutsumi,H., Tanaka,T., Ohashi,N., Masuno,H., Tamamura,H., Hiramatsu,K., Araki,T., Ueda,S., Oishi,S., Fujii,N. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents. Biopolymers (peptide Science) 2007; 88(-2-):279-289. >>> TN14003, 4F-benzoyl; SC; Mice; ; Cancer.

P8493 Thomas,E.K., Cancelas,J.A., Chae,H.D., Cox,A.D., Keller,P.J., Perrotti,D., Neviani,P., Druker,B.J., Setchell,K.D.R., Zheng,Y., Harris,C.E., Williams,D.A. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. CANCER CELL 2007; 12(-5-):467-478. >>> NSC23766; SC; Mice (SCID); 2002; 17 days; Cancer (leukemia).

P8489 Song,P., Sekhon,H.S., Lu,A., Arredondo,J., Sauer,D., Gravett,C., Mark,G.P., Grando,S.A., Spindel,E.R. M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion. Cancer Research 2007; 67(-8-):3936-3944. >>> Darifenacin; DMSO; PBS; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; plasma levels taken; dose-response (p. 3941); cancer (lung); tumors implanted in right flank; M3 receptor antagonist; xenograft; animal info (6-7 weeks old).

P8467 Zhang,Y.M., Bressler,J.P., Neal,J., Lal,B., Bhang,H.E.C., Laterra,J., Pomper,M.G. ABCG2/BCRP expression modulates D-luciferin-based bioluminescence imaging. Cancer Research 2007; 67(-19-):9389-9397. >>> Luciferin; SC; Mice (nude); 1007D; 1 hour; Cancer; bioluminescence imaging (BLI); animal info (female, nude); tumor cells injected SC; pg 939s shows images with pumps implanted.

P8463 Shen,X.Z., Li,P., Weiss,D., Fuchs,S., Xiao,H.D., Adams,J.A., Williams,I.R., Capecchi,M.R., Taylor,W.R., Bernstein,K.E. Mice with enhanced macrophage angiotensin-converting enzyme are resistant to melanoma. American Journal of Pathology 2007; 170(-6-):2122-2134. >>> Captopril; losartan; SC; Mice; 2 weeks; Functionality of mp verified by systolic blood pressure; enzyme inhibitor (ACE); cancer (melanoma); immunology; animal info (C56BL/6, wt, ACE 10/10, 8wks old).

P8456 Garbaccio,R.M., Tasbera,E.S., Neilson,L.A., Coleman,P.J., Fraley,M.E., Olson,C., Bergman,J., Torrent,M., Buser,C.A., Rickert,K., Walsh,E.S., Hamilton,K., Lobell,R.B., Tao,W.K., South,V.J., Diehl,R.E., Davide,J.P., Yan,Y.W., Kuo,L.C., Li,C.Z., Prueksaritanont,T., Fernandez-Metzler,C., Mahan,E.A., Slaughter,D.E., Salata,J.J., Kohl,N.E., Huber,H.E., Hartman,G.D. Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSP. BIOORGANIC&MEDICINAL CHEMISTRY LETTERS 2007; 17(-20-):5671-5676. >>> Kinesin spindle protein inhibitor; SC; Mice (nude); 2001D; 22-24 hours; Cancer (ovarian carcinoma); animal info (athymic nude).

P8443 Banach-Petrosky,W., Jessen,W.J., Ouyang,X., Gao,H., Rao,J., Quinn,J., Aronow,B.J., bate-Shen,C. Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice. Cancer Research 2007; 67(-19-):9089-9096. >>> Testosterone propionate; PEG 400; SC; Mice; 2004; 7 months; Controls received mp w/ vehicle, or no treatment; replacement therapy (castration); dose-response (fig 1A); long-term study; pumps replaced every 28 days; cancer prostate; animal info (male, C57Bl/65X129/SvImJ, 6 wks old).

P8437 Henke,E., Perk,J., Vider,J., de Candia,P., Chin,Y., Solit,D.B., Ponomarev,V., Cartegni,L., Manova,K., Rosen,N., Benezra,R. Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. NATURE BIOTECHNOLOGY 2008; 26(-1-):91-100. >>> Oligonucleotide, antisense, peptide conjugated; oligonucleotide, phosphorothioate antisense; peptide, F3; TBS; SC; Mice (nude); mice; 1007D; 1002; 14, 21 days; Controls received mp w/ vehicle or control peptide and oligo in non-conjugated form, or rcId1-PCAO; comparison of IV injections vs. mp; pumps replaced after 14 days; no stress (see pg. 95, 97); stability verified after 24 hours in 37 C, plasma up to 28 days in 37 C saline; antisense (Id1, rcId1); cancer (breast, lung carcinoma); peptides; toxicology; animal info (female, nude NCR; male, C57J/B6); antisense oligos covalently coupled to address peptide that targets tumor endothelial cells; "no adverse effects on treated mice have been observed." (p. 97).

P8436 Rabbani,Z.N., Batinic-Haberle,I., Anscher,M.S., Huang,J., Day,B.J., Alexander,E., Dewhirst,M.W., Vujaskovic,Z. Long-term administration of a small molecular weight catalytic metalloporphyrin antioxidant, AEOL 10150, protects lungs from radiation-induced injury. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 2007; 67(-2-):573-580. >>> AEOL 10150; SC; Rat; 2002; 10 weeks; 8 days; Controls received mp w/ vehicle; functionality of mp verified by plasma AEOL 10150 concentrations; dose-response (fig. 4); long-term study; pumps replaced every 2 weeks; half-life (p. 574), short; cancer; animal info (female, Fisher-344, 150-170 grams); "Osmotic mini-pumps provided consistent and dose-dependent delivery of AEOL 10150," "a continuous availability of antioxidant via osmotic infusion pumps throughout the study." (p. 575).

P8393 Yao,W.Q., Zhuo,J.C., Burns,D.M., Xu,M.Z., Zhang,C.L., Li,Y.L., Qian,D.Q., He,C.H., Weng,L.K., Shi,E., Lin,Q.Y., Agrios,C., Burn,T.C., Caulder,E., Covington,M.B., Fridman,J.S., Friedman,S., Katiyar,K., Hollis,G., Li,Y.L., Liu,C.N., Liu,X.D., Marando,C.A., Newton,R., Pan,M., Scherle,P., Taylor,N., Vaddi,K., Wasserman,Z.R., Wynn,R., Yeleswaram,S., Jalluri,R., Bower,M., Zhou,B.B., Metcalf,B. Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer. Journal of Medicinal Chemistry 2007; 50(-4-):603-606. >>> INCB3619; trastuzumab; SC; Mice; 28 days; Controls received mp w/ vehicle; enzyme inhibitor (HER-2 sheddase); cancer (breast); animal info (BT-474-SC1); trastuzumab is a humanized anti-HER-2 monoclonal antibody.

P8366 Dorrell,M.I., Aguilar,E., Scheppke,L., Barnett,F.H., Friedlander,M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2007; 104(-3-):967-972. >>> Vascular endothelial growth factor, aptamer; EMD472523; T2-TrpRS; PBS; CSF/CNS (intratumoral); Rat; 2001D; 2ML2; 2ML4; 3,6 days; 24 hours; Controls received mp w/ vehicle; cancer (gliosarcoma); animal info (male, Fischer, 344); EMD472523 is an integrin antagonist, VEGF aptamer is chemically identical to Macugen; T2 is a proteolytic fragment of tryptophan tRNA synthetase; all agents have angiostatic activity; tissue perfusion (tumor).

P8357 Mulder,W.J.M., van der Schaft,D.W.J., Hautvast,P.A.I., Strijkers,G.J., Koning,G.A., Storm,G., Mayo,K.H., Griffioen,A.W., Nicolay,K. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB Journal 2007; 21(-2-):378-383. >>> Endostatin; anginex; SC; Mice; 2 weeks; 3 days; Controls received mp w/ saline; cancer (melanoma); peptides; MRI; animal info (C57BL/6, 6 weeks old); antiangiogenesis.

P8332 Prevost,G.P., Lonchampt,M.O., Holbeck,S., Attoub,S., Zaharevitz,D., Alley,M., Wright,J., Brezak,M.C., Coulomb,H., Savola,A., Huchet,M., Chaumeron,S., Nguyen,Q.D., Forgez,P., Bruyneel,E., Bracke,M., Ferrandis,E., Roubert,P., Demarquay,D., Gespach,C., Kasprzyk,P.G. Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric G alpha /G beta gamma protein complex. Cancer Research 2006; 66(-18-):9227-9234. >>> BIM-46174; Rat; 6 days; No stress (see pg. 9231); cancer (lung); toxicology.

P8331 Joppa,M.A., Gogas,K.R., Foster,A.C., Markison,S. Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice. Peptides 2007; 28(-3-):636-642. >>> Agouti-related peptide (83-132); Saline, sterile; CSF/CNS; Mice; 1003D; 72 hours; Controls received mp w/ vehicle; cancer (colon adenocarcinoma); peptides; animal info (male, BALB/C, 6 weeks old, 22 grams); Research Diets D12689B.

P8330 Raafat,A., Zoltan-Jones,A., Strizzi,L., Bargo,S., Kimura,K., Salomon,D., Callahan,R. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis. ONCOGENE 2007; 26(-5-):662-672. >>> Imatinib mesylate; SC; Mice (transgenic); 2001; 1,3,4,5,7 days; Controls received mp w/ water; dose-response (fig 2); no stress (see pg. 663); cancer (mammary); animal info (female, FVB/N, 10 wks old); antiangiogenic; "Continuous release of Gleevec for a week resulted in 33% inhibition of tumor growth by day 2 and 66% by day 4." (p. 668).

P8323 Shibata,M.A., Morimoto,J., Doi,H., Morishima,S., Naka,M., Otsuki,Y. Electrogene therapy using endostatin, with or without suicide gene therapy, suppresses murine mammary tumor growth and metastasis. Cancer Gene Therapy 2007; 14(-3-):268-278. >>> Ganciclovir; Saline; SC; Mice; 2002; 8 weeks; Controls received mp w/ agent and empty control vector; long-term study; pumps replaced every 14 days; no stress (see pg. 271); cancer (mammary adenocarcinoma); animal info (BALB/C, female, 20-24 grams).

P8308 Price,R.J., Walters,D.G., Finch,J.M., Gabriel,K.L., Capen,C.C., Osimitz,T.G., Lake,B.G. A mode of action for induction of liver tumors by Pyrethrins in the rat. TOXICOLOGY AND APPLIED PHARMACOLOGY 2007; 218(-2-):186-195. >>> Uridine, bromodeoxy-; Rat; 2ML1; 7 days; Cancer (liver); toxicology; animal info (male, female, Sprague-Dawley CD, 10-11 wks old); labeling of hepatocytes.

P8305 Mook,O.R., Baas,F., de Wissel,M.B., Fluiter,K. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. MOLECULAR CANCER THERAPEUTICS 2007; 6(-3-):833-843. >>> RNA, small interfering; RNA, small interfering, LNA-modified; Radio-isotopes, 3H-; SC; Mice (nude); 1007D; 7 days; 48 hours; Controls received mp w/ mismatch siRNA or saline; comparison of IV injections vs. mp; stability verified by incubation in mouse serum; half-life (p. 837) increased in LNA-modified; unmodified completely degraded in<5 hours; cancer (pancreatic); animal info (NMRI nu/nu, 8-10 weeks old); siRNA against RNA polymerase II, enhanced GFP, or mismatch.

P8302 Zhang,X.F., Connolly,C., Duquette,M., Lawler,J., Parangi,S. Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model. Cancer Letters 2007; 247(-1-):143-149. >>> Thrombospondin-1, three type 1 repeats; PBS; SC; Mice (SCID); 1007D; 7 days; Controls received mp w/ vehicle; comparison of IP injections vs. mp; stability verified by incubation in pump, 7 days; cancer (pancreatic); peptides; animal info (female, SCID, 4-6 weeks old); antiangiogenesis therapy; 3TSR; "Continuous administration of 3TSR reduced dosage and improved therapeutic potency." p. 146.

P8301 Badn,W., Hegardt,P., Fellert,M.A., Darabi,A., Esbjoernsson,M., Smith,K.E., Janelidze,S., Salford,L.G., Visse,E., Siesjoe,P. Inhibition of inducible nitric oxide synthase enhances anti-tumour immune responses in rats immunized with IFN-gamma-secreting glioma cells. SCANDINAVIAN JOURNAL OF IMMUNOLOGY 2007; 65(-3-):289-297. >>> L-NAME; L-NIL; Saline; IP; Rat; 2001; 1 week; 14, 28 days; Controls received mp w/ vehicle; dose-response (fig. 3); comparison of IP injections vs. mp; enzyme inhibitor (Nitric oxide synthase, iNOS); cancer (glioma); L-NIL is L-N6- (1-iminsethyl) -L-lysine.

P8295 Uesato,N., Fukui,K., Maruhashi,J., Tojo,A., Tajima,N. JTE-607, a multiple cytokine production inhibitor, ameliorates disease in a SCID mouse xenograft acute myeloid leukemia model. Experimental Hematology 2006; 34(-10-):1385-1392. >>> JTE-607; Cyclodextrin, 2-hydroxypropyl-beta; SC; Mice (SCID); 2001; 7 days; Controls received mp w/ vehicle; comparison of bolus injections vs. mp; cancer (leukemia); animal info (8-9 weeks old); xenograft; multiple cytokine inhibitor; antileukemic; "Administration of JTE-607 using osmotic pumps reduced the number of leukemic cells...and significantly prolonged the mouse survival..." p. 1386.

P8294 Yagi,H., Ueda,M., Jinno,H., Aiura,K., Mikami,S., Tada,H., Seno,M., Yamada,H., Kitajima,M. Anti-tumor effect in an in vivo model by human-derived pancreatic RNase with basic fibroblast growth factor insertional fusion protein through antiangiogenic properties. CANCER SCIENCE 2006; 97(-12-):1315-1320. >>> Fibroblast growth factor, basic; CL-RFN89; PBS; Mice (nude); ; Cancer (carcinoma); animal info (4 weeks old, female, Balb/C, nude); antiangiogenesis; tumor cells in right flank, agent is an insertional-fusion protein.

P8293 Suzuki,E., Kim,S., Cheung,H.K., Corbley,M.J., Zhang,X.M., Sun,L.H., Shan,F., Singh,J., Lee,W.C., Albelda,S.M., Ling,L.E. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Research 2007; 67(-5-):2351-2359. >>> SM16; Captisol; SC; Mice; 2004; 10 days; Controls received mp w/ vehicle; SM16 plasma levels taken; dose-response (p. 2354); enzyme inhibitor (ALK5 kinase); cancer (mesothelioma); animal info (Balb/c, 6-8 weeks old, 19-24 grams); "This mode of delivery [pumps] maintains consistent plasma levels of SM16 over the course of the study." p. 2356.

P8289 Banach-Petrosky,W., Ouyang,X.S., Gao,H., Nader,K., Ji,Y., Suh,N., DiPaola,R.S., bate-Shen,C. Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1; Pten mutant mice. Clinical Cancer Research 2006; 12(-19-):5895-5901. >>> Vitamin D3, 1,25-dihydroxy-; Propylene glycol; SC; Mice; 2004; 1-4 months; Controls received mp w/ vehicle; long-term study; pumps replaced every 4 weeks; stability verified by serum calcium levels; cancer (prostate); animal info (4-7 months old, male).

P8287 Manabe,T., Okino,H., Maeyama,R., Mizumoto,K., Tanaka,M., Matsuda,T. New infusion device for trans-tissue, sustained local delivery of anticancer agent to surgically resected tissue: Potential use for suppression of local recurrence of pancreatic cancer. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS 2005; 73B(-1-):203-207. >>> Gemcitabine; SC; Mice (nude); 1007D; 7 days; Tissue perfusion (intratumoral); comparison of IP injections; cancer (pancreatic); animal info (five week old); pump used as part of a novel infusion device; pictures of device p. 205; PE tubing used to connect pump to perfusion device; continuous infusion resulted in macroscopically undetectable tumors after day 6.

P8286 Ying,H., Biroc,S.L., Li,W.W., Alicke,B., Xuan,J.A., Pagila,R., Ohashi,Y., Okada,T., Kamata,Y., Dinter,H. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. MOLECULAR CANCER THERAPEUTICS 2006; 5(-9-):2158-2164. >>> Fasudil; Saline; SC; Mice (nude); 21 days; Controls received mp w/ vehicle; cancer (lung).

P8285 Yang,L.H., Jackson,E., Woerner,B.M., Perry,A., Piwnica-Worms,D., Rubin,J.B. Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Research 2007; 67(-2-):651-658. >>> AMD3465; PBS; SC; Mice; ; Controls received mp w/ vehicle; cancer (brain); BLI, IVIS imaging performed; 0.25 ul/hr pump used.

P8276 Rustamzadeh,E., Hall,W.A., Todhunter,D.A., Vallera,V.D., Low,W.C., Liu,H.Y., Panoskaltsis-Mortari,A., Vallera,D.A. Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice. International Journal of Cancer 2006; 120(-2-):411-419. >>> DTAT; Saline; CSF/CNS; Mice; 1007D; ; Controls received mp w/ vehicle; dose-response (table 1); comparison of bolus ICV injections vs. mp; cancer (glioblastoma); toxicology; peptides; animal info (C57BL/6, female, 12 weeks old); diptheria toxin; "delivery of DTAT resulted in about a 16 fold increase in maximum tolerated dose." (p. 411); "The results of this experiment indicate that the toxicity of uPAR can be reduced by CED (mp) delivery." (p. 416).

P8271 Strieth,S., Eichhorn,M.E., Sutter,A., Jonczyk,A., Berghaus,A., Dellian,M. Antiangiogenic combination tumor therapy blocking alpha v-integrins and VEGF-receptor-2 increases therapeutic effects in vivo. International Journal of Cancer 2006; 119(-2-):423-431. >>> EMD270179; SU5416; DMSO; HCL; SC; IP; Hamster; 2001; 7 days; Controls received mp w/ vehicle; functionality of mp verified by EMD270179 plasma levels; no stress (see pg. 425); half-life (p. 427); "In consideration of the short half-lives of cRGD peptides we decided to apply antiangiogenic cRGD peptides continuously by osmotic pumps." cancer (A-Mel-3); peptides; animal info (syrian golden, 6-8 weeks old, 60 grams); 50% DMSO used; "All animals tolderated pump placement well...in all animals receiving IP osmotic pumps we found quite consistent plasma levels on days 1, 4, 6, and 7 after pump implantation." (p. 425).

P8244 Redjal,N., Chan,J.A., Segal,R.A., Kung,A.L. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. Clinical Cancer Research 2006; 12(-22-):6765-6771. >>> AMD 3100; PBS; SC; Mice; 15 days; Controls received mp w/ vehicle; comparison of SC injections vs. mp; cancer (glioma); bioluminescence, IVIS imaging system; combination therapy; CXCR4 inhibitor.

P8226 Michaud-Levesque,J., Demeule,M., Beliveau,R. In vivo inhibition of angiogenesis by a soluble form of melanotransferrin. Carcinogenesis 2007; 28(-2-):280-288. >>> Melanotransferrin, soluble, truncated recomb. human; melanotransferrin, [125I]-soluble, truncated recomb. human; Ringers's solution; HEPES solution; SC; Mice (nude); 1007D; 7 days; Controls received mp w/ vehicle; dose-response (fig. 6); comparison of SC injections vs. mp; half-life (p. 285) ~7.6 hours + or - 0.9 hours; cancer; peptides; animal info (female, athymic CD-1-nuBr, 5-10 weeks old); "The use of ALZET osmotic pump infusion technique provided a higher therapeutic efficacy as compared with repeated S.C. injections, emphasizing the advantages of constant infusion rather than pulse-dose drug inputs for antiangiogenic effects." (p. 287).

P8224 Menon,J., Soto-Pantoja,D.R., Callahan,M.F., Cline,J.M., Ferrario,C.M., Tallant,E.A., Gallagher,P.E. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Research 2007; 67(-6-):2809-2815. >>> Angiotensin (1-7); Saline; heparin; IV (jugular); Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; no stress (see pg. 2810); cancer (lung); peptides; animal info (male, athymic, 2-4 weeks old, 15-20 grams); "During the infusion period, the animals maintained their body weight as well as food and water consumption and showed no evidence of reduced motor function. Additionally, no gross pathological abnormalities were observed in major organs..indicating a lack of toxic side effects." (p. 2810).

P8209 Masunaga,S.I., Kasaoka,S., Maruyama,K., Nigg,D., Sakurai,Y., Nagata,K., Suzuki,M., Kinashi,Y., Maruhashi,A., Ono,K. The potential of transferrin-pendant-type polyethyleneglycol liposomes encapsulating decahydrodecaborate-10B (GB-10) as 10B-carriers for boron neutron capture therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 2006; 66(-5-):1515-1522. >>> Uridine, bromodeoxy-; Saline, physiological; SC; Mice; 5 days; Cancer (squamous cell carcinoma); animal info (female, C3H/He, 8-11 wks old, 20-25g.).

P8208 Martens,T., Schmidt,N.O., Eckerich,C., Fillbrandt,R., Merchant,M., Schwall,R., Westphal,M., Lamszus,K. A novel one-armed anti-c-met antibody inhibits glioblastoma growth in vivo. Clinical Cancer Research 2006; 12(-20-):6144-6152. >>> Antibody, anti-c-Met, OA5D5; Histidine; CSF/CNS (intratumoral); Mice (nude); 2004; 12, 21, 28 days; Controls received mp w/ vehicle; cancer (glioblastoma); ALZET brain infusion kit 2 used; animal info (male, NMRI-nu/nu, 6-8 wks old); "Because the OA-5D5 antibody is a relatively large but stable molecule, convection-enhanced drug delivery (by mp) was ideally suited to deliver it in our orthotopic model." (p.6151); tissue perfusion (tumor).

P8203 Masunaga,S., Nagasawa,H., Nagata,K., Suzuki,M., Uto,Y., Hori,H., Kinashi,Y., Ono,K. Dependency of the effect of a vascular disrupting agent on sensitivity to tirapazamine and gamma-ray irradiation upon the timing of its administration and tumor size, with reference to the effect on intratumor quiescent cells. Journal of Cancer Research and Clinical Oncology 2007; 133(-1-):47-55. >>> Uridine, bromodeoxy-; Saline, physiological; SC; Mice; 5, 8 days; Cancer (carcinoma); animal info (female, 8-11 wks old).

P8173 Marchal,F., Tran,N., Marchal,S., Leroux,A., Marchal,C., Bolotine,L., Guillemin,F.O., Villemot,J.P. Development of an HT29 liver metastases model in nude rats. Oncology Reports 2005; 14(-5-):1203-1207. >>> Cyclosporin A; IP; Rat (nude); 2ML4; 4 weeks; Controls received no treatment; no stress (see pg. 1204); cancer (colorectal); peptides; animal info (male, athymic Rowett nude, 300 grams).

P8169 Masunaga,S.I., Uto,Y., Nagasawa,H., Hori,H., Nagata,K., Suzuki,M., Kinashi,Y., Ono,K. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. dependency on p53 status of tumor cells and the effects on intratumor quiescent cells. Anticancer Research 2006; 26(-2A-):1261-1270. >>> Uridine, bromodeoxy-; Saline, physiological; SC; Mice (nude); 5, 7 days; Cancer (squamous cell carcinoma); animal info (BALB/cA, C3H/He, 6-7 weeks old, 22 grams); labeling of tumor 'P' cells.

P8162 Tjomsland,V., El-Salhy,M. Anti-tumour effects of triple therapy with octreotide, galanin and serotonin in comparison with those of 5-fluorouracil/leukovorin on human colon cancer. INTERNATIONAL JOURNAL OF ONCOLOGY 2005; 27(-2-):427-432. >>> Octreotide; galanin, synthetic human; serotonin; IP; Mice (nude); 1002; 14 days; No stress (see pg. 429); cancer (colon); animal info (female, BALB/cA-nu, 6-8 weeks old, 20 grams); "The animals treated with triple therapy (mp) did not show any sign of discomfort or suffering during the experiment and held a stable body weight." (p. 429).

P8159 Bihorel,S., Camenisch,G., Gross,G., Lemaire,M., Scherrmann,J.M. Influence of hydroxyurea on imatinib mesylate (gleevec) transport at the mouse blood-brain barrier. Drug Metabolism and Disposition 2006; 34(-12-):1945-1949. >>> Imatinib mesylate; hydroxyurea; Saline; SC; Rat; 2ML2; 7, 14 days; Half-life (p. 1948) hydroxyurea<1 hour in rats; enzyme inhibitor (ribonucleotide reductase); cancer (glioblastoma); animal info (Hanover Wistar, 270-310 grams); ATP competitive inhibitor; A.K.A, Gleevec or STI571.

P8145 Grommes,C., Landreth,G.E., Sastre,M., Beck,M., Feinstein,D.L., Jacobs,A.H., Schlegel,U., Heneka,M.T. Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. MOLECULAR PHARMACOLOGY 2006; 70(-5-):1524-1533. >>> Pioglitazone; DMSO; PBS; CSF/CNS (intratumoral); Rat; 2ML4; 3, 6, 9, 14, 21 days; Controls received mp w/ vehicle; comparison of oral admin. vs. mp; no stress (see p.1532); stability verified by in vitro incubation at 37 celsius for 21 days; cancer (glioma); ALZET brain infusion kit used; animal info (Sprague-Dawley, 200-250g.); 0.1% DMSO; Antineoplastic; tissue perfusion (tumor).

P8140 Husen,B., Huhtinen,K., Saloniemi,T., Messinger,J., Thole,H.H., Poutanen,M. Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts. Endocrinology 2006; 147(-11-):5333-5339. >>> B10721325; estrone; DMSO; propanediol; SC; Mice (nude); 1002; 2 weeks; Controls received mp w/ vehicle; replacement therapy (ovariectomy); dose-response (p.5335); pumps replaced after 14 days; enzyme inhibitor (hydroxysteroid 17 beta dehydrogenase 1); cancer (breast); animal info (female, BALB/cA Bom-v, Crl: nu/nu, 10-11 wks old); 50%DMSO; endocrinology.

P8110 Iwasaki,Y., Ueda,M., Yamada,T., Kondo,A., Seno,M., Tanizawa,K., Kuroda,S., Sakamoto,M., Kitajima,M. Gene therapy of liver tumors with human liver-specific nanoparticles. Cancer Gene Therapy 2007; 14(-1-):74-81. >>> Ganciclovir; Water, sterile; SC; Rat (nude); 12 days; Controls received mp w/ agent and plasmid w/out gene therapy gene; no stress (see p.78); cancer (liver); gene therapy; animal info (male, F344/N, nu/nu, 5 wks old, 180g., NuE hepatic tumors); GCV acts as pro-drug for HSV-tk expression plasmid gene therapy.

P8109 Dirkx,A.E.M., Egbrink,M.G.A.O., Castermans,K., van der Schaft,D.W.J., Thijssen,V.L.J.L., Dings,R.P.M., Kwee,L., Mayo,K.H., Wagstaff,J., Steege,J.C.A.B., Griffioen,A.W. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB Journal 2006; 20(-6-):621-630. >>> Anginex; endostatin; BSA; angiostatin; Saline; SC; Mice; 2 weeks; 7, 11 days; Controls received mp w/ BSA or no treatment; dose-response (fig.5); cancer (melanoma, colon carcinoma); animal info (C57BL/6).

P8052 Brown,J.R., Fuster,M.M., Li,R.X., Varki,N., Glass,C.A., Esko,J.D. A disaccharide-based inhibitor of glycosylation attenuates metastatic tumor cell dissemination. Clinical Cancer Research 2006; 12(-9-):2894-2901. >>> Disaccharide, AcGnG-NM; DMSO; propylene glycol; SC; Mice; 2004; 2, 4 weeks; Controls received mp w/ vehicle; stability verified by incubation in mouse serum; cancer (lung carcinoma, B16Bl6 melanoma); animal info (c57BL/6 Es1(e); 8-12 wk old, lung metastases); 50% DMSO.

P8051 Wang,J.R., Zheng,H., Qiu,X.H., Kulkarni,A., Fink,L.M., Hauer-Jensen,M. Modulation of the intestinal response to ionizing radiation by anticoagulant and non-anticoagulant heparins. THROMBOSIS AND HAEMOSTASIS 2005; 94(-5-):1054-1059. >>> Nadroparin; sr-80258a; Saline, physiological; SC; Rat; 2002; 17 days; Controls received mp w/ vehicle; half-life (p.1055) 3.5 hrs. (nadroparin); cancer (radiation therapy); cardiovascular; toxicology; animal info (male,Sprague-Dawley, 43-49 days old, 175-200 grams, small bowel irradiation).

P8041 Durando,M., Kass,L., Piva,J., Sonnenschein,C., Soto,A.M., Luque,E.H., Munoz-de-Toro,M. Prenatal bisphenol A exposure induces preneoplastic lesions in the mammary gland in Wistar rats. Environmental Health Perspectives 2007; 115(-1-):80-86. >>> Bisphenol A; DMSO; SC; Rat (pregnant); 1002; 14 days; Controls received mp w/ vehicle; teratology; animal info (Wistar, female); cancer.

P8018 Kim,K.S., Sengupta,S., Berk,M., Kwak,Y.G., Escobar,P.F., Belinson,J., Mok,S.C., Xu,Y. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Research 2006; 66(-16-):7983-7990. >>> Lysophosphatidic acid; PBS; IP; Mice (nude); 1002; 21 days; Controls received mp w/ vehicle; pumps replaced every 15 days; cancer (ovarian carcinoma); animal info (female, nu/nu, skov3 tumors placed on ovaries); mp siliconized by placing 100 ul sigmacote into mp, removing liquid and letting the mp dry before agent is introduced; developed mouse model of metastatic ovarian cancer.

P8016 Fridman,J.S., Caulder,E., Hansbury,M., Liu,X.D., Yang,G.J., Wang,Q., Lo,Y., Zhou,B.B., Pan,M., Thomas,S.M., Grandis,J.R., Zhuo,J.C., Yao,W.Q., Newton,R.C., Friedman,S.M., Scherle,P.A., Vaddi,K. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clinical Cancer Research 2007; 13(-6-):1892-1902. >>> Marimastat; INCB3619; SC; Mice; mice (nude); 7, 14 days; Controls received mp w/ vehicle; enzyme inhibitor (metalloprotease); cancer (squamous cell carcinoma, breast, lung carcinoma); toxicology; animal info (BALB/c, CD-1 nu/nu); ErbB ligand shedding inhibitor; half-life (pg 1894) "<2h in the mouse" 6.1h in larger animals.

P8002 Tsai,C.H., Hong,J.H., Hsieh,K.F., Hsiao,H.W., Chuang,W.L., Lee,C.C., McBride,W.H., Chiang,C.S. Tetracycline-regulated intratumoral expression of interleukin-3 enhances the efficacy of radiation therapy for murine prostate cancer. Cancer Gene Therapy 2006; 13(-12-):1082-1092. >>> Doxycycline; PBS; SC; Mice; 2001; 7 days; Controls received mp w/ vehicle; cancer (prostate); animal info (C57BL/6J, 7-8 weeks old); paper states incorrect pump model.

P7999 Ueda,S., Nakamura,T., Yamada,A., Teratani,A., Matsui,N., Furukawa,S., Hoshino,Y., Narita,M., Yodoi,J., Nakamura,H. Recombinant human thioredoxin suppresses lipopolysaccharide-induced bronchoalveolar neutrophil infiltration in rat. LIFE SCIENCES 2006; 79(-12-):1170-1177. >>> Thioredoxin, human recomb.; SC; Mice (nude); 2002; 2 weeks; Controls received mp w/ PBS; plasma levels taken; cancer (colon, carcinoma); peptides; animal info (female, 6 weeks old, nude); xenograft.

P7975 Pyrko,P., Wang,W., Markland,F.S., Swenson,S.D., Schmitmeier,S., Schonthal,A.H., Chen,T.C. The role of contortrostatin, a snake venom disintegrin, in the inhibition of tumor progression and prolongation of survival in a rodent glioma model. Journal of Neurosurgery 2005; 103(-3-):526-. >>> Contortrostatin; CSF/CNS (intratumorally); Mice; 2 weeks; Controls received mp w/ PBS; plasma levels taken; cancer (glioma); brain tissue distribution; snake venom disintegrin; "agent was well tolerated by animals and lacks obvious neurotoxic side effects. All the contortrostatin treated mice survived the entire treatment period and continued to do well for seven more days after the termination." p. 533; tygon tubing used; tissue perfusion (tumor).

P7965 O'Connor,O.A., Smith,E.A., Toner,L.E., Teruya-Feldstein,J., Frankel,S., Rolfe,M., Wei,X.H., Liu,S.J., Marcucci,G., Chan,K.K., Chanan-Khan,A. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. Clinical Cancer Research 2006; 12(-9-):2902-2911. >>> Oblimersen; Saline; SC; Mice (SCID); 2004; 28 days; Stress/adverse reaction: (see pg. 2907), infection (pumps are provided sterile); cancer (lymphoma); animal info (5-7 weeks old, SCID); xenograft; bcl-2 antisense molecule.

P7964 Mortlock,A.A., Foote,K.M., Heron,N.M., Jung,F.H., Pasquet,G., Lohmann,J.J., Warin,N., Renaud,F., Savi,C.D., Roberts,N.J., Johnson,T., Dousson,C.B., Hill,G.B., Perkins,D., Hatter,G., Wilkinson,R.W., Wedge,S.R., Heaton,S.P., Odedra,R., Keen,N.J., Crafter,C., Brown,E., Thompson,K., Brightwell,S., Khatri,L., Brady,M.C., Kearney,S., McKillop,D., Rhead,S., Parry,T., Green,S. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J.Med.Chem. 2007/3/21; Online only(--):-. >>> AZD1152; Tris buffer; SC; Mice; 2001D; 48 hours; Enzyme inhibitor (aurora kinase); cancer; animal info (male, Swiss, nu/nu); PK data; xenograft; tumor cells on dorsal flank.

P7944 Shao,T.C., Li,H.L., Kasper,S., Matusik,R., Ittmann,M., Cunningham,G.R. Comparison of the growth-promoting effects of testosterone and 7-alpha-methyl-19-nor-testosterone (MENT) on the prostate and levator ani muscle of LPB-Tag transgenic mice. PROSTATE 2006; 66(-4-):369-376. >>> Testosterone; nortestosterone, 7 alpha-methyl-19-; Cyclodextrin; SC; Mice (transgenic); 2004; 4 weeks; Replacement therapy (orchidectomy); cancer (prostate); animal info (male, transgenic, 32 grams, ORX); MENT (7-alpha-methyl-19-nor-testosterone) and testosterone dissolved in 45% cyclodextrin.

P7935 Chen,J.C., Chen,Y., Wu,J.M., Su,Y.H., Tai,K.F., Tseng,S.H. Effects of irradiated tumor vaccine and infusion of granulocyte-macrophage colony-stimulating factor and interleukin-12 on established gliomas in rats. CANCER IMMUNOLOGY IMMUNOTHERAPY 2006; 55(-7-):873-883. >>> Granulocyte-macrophage colony-stimulating factor, recomb. mouse; interleukin-12, recomb. mouse; BSA; PBS; SC; Rat; 2002; 14 days; Controls received mp w/ vehicle or no treatment; cancer (RT-2 glioma); peptides; animal info (Fischer, 200-350 grams, SC and ICV tumors); "continuously infused cytokine using an osmotic mini pump to...avoid the side effects of a single large dose of cytokine and one with a concept similar to that of gene-therapy." (p. 874).

P7931 Yurimoto,S., Miyakawa,A., Okuzawa,A., Sakamoto,S., Sakamoto,K., Hosoda,S., Kamano,T. Enhancement of the anti-tumor activity of S-1 by low-dose cisplatin in mice bearing the sarcoma-180 model. Anti-cancer Drugs 2005; 16(-10-):1109-1114. >>> Fluorouracil, 5-FU; IP; Mice; 1007D; 8 days; Cancer (sarcoma-180); animal info (six week old, male, 30 grams); tumor cells in abdomen; chemotherapeutic.

P7922 Segrelles,C., Moral,M., Lara,M.F., Ruiz,S., Santos,M., Leis,H., Garcia-Escudero,R., Martinez-Cruz,A.B., Martinez-Palacio,J., Hernandez,P., Ballestin,C., Paramio,J.M. Molecular determinants of Akt-induced keratinocyte transformation. ONCOGENE 2006; 25(-8-):1174-1185. >>> Rapamycin; PBS; BSA; SC; Mice (nude); 2002; 2 weeks; Cancer; animal info (nude, 5-6 weeks old, female).

P7906 Houli,N., Loh,S.W., Giraud,A.S., Baldwin,G.S., Shulkes,A. Mitogenic effects of both amidated and glycine-extended gastrin-releasing peptide in defunctioned and azoxymethane-treated rat colon in vivo. REGULATORY PEPTIDES 2006; 134(-1-):9-16. >>> Gastrin-releasing peptide, amidated; gastrin-releasing peptide, glycine extended; PBS; IP; Rat; 2ML4; 4 weeks; Controls received mp w/ vehicle; no stress (see pg. 11-12); cancer (colorectal); peptides; animal info (male, Sprague-Dawley, 250-350g); "All animals remained healthy during the 4 week experimental period and rats in the different experimental groups gained weight at the same rate." (p. 11-12).

P7905 Shir,A., Ogris,M., Wagner,E., Levitzki,A. EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLOS MEDICINE 2006; 3(-1-):125-135. >>> RNA, double stranded; polyinosine-cytosine (poly IC) dsRNA; Non-viral vector; SC; Mice; 2001D; 2 days; Per communication with author on 8/11/07, "We did not have any particular problems with the anesthesia exposure. For the pump replacement procedure Ketamine/Xylazine 2% (0.85ml/0.15ml), 40-50 ul IP per mouse (25 gram) was used. Replacing of the pump was not problematic either. The skin was closed with a surgical clips which are less traumatic to the mice and are easily applied and removed." 2001D pump replaced every day for two days total duration; synthetic dsRNA was attached to a non-viral vector (PEI-PEG-EGF beta PEI-Mel complexes) with specificity to the epidermal growth factor receptor (EGFR); controls received vector only (no poly IC); tissue perfusion (intratumoral); cancer (glioblastoma, breast, adenocarcinoma).

P7904 Harding,T.C., Lalani,A.S., Roberts,B.N., Yendluri,S., Luan,B., Koprivnikar,K.E., Gonzalez-Edick,M., Guang,H.T., Musterer,R., VanRoey,M.J., Ozawa,T., LeCouter,R.A., Deen,D., Dickinson,P.J., Jooss,K. AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma. MOLECULAR THERAPY 2006; 13(-5-):956-966. >>> Adeno-associated virus serotype 8 vector, recomb.; CSF/CNS (intratumoral); Rat; 2001D; 24 hours; Controls received mp w/ AAV control; cancer (glioblastoma multiforme, u-251 MG); gene thrapy; animal info (male, athymic, 6 wk. old); rAAV contains soluble VEGF inhibitor, sVEGFR1/R2; "Implantation of the mini pump allows the slow infusion of a rAAV vector...to transduce more effectively the intracranial tumor mass." (pg. 962); antiangiogenesis.

P7902 Husen,B., Huhtinen,K., Poutanen,M., Kangas,L., Messinger,J., Thole,H. Evaluation of inhibitors for 17 beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme. MOLECULAR AND CELLULAR ENDOCRINOLOGY 2006; 248(-1-2-):109-113. >>> Estrone; B10720512; B10721325; B10720440; B10720511; B10715817; DMSO; propanediol; SC; Mice (nude); 1002; 4 weeks; 14 days; Controls received mp w/ vehicle; replacement therapy (ovariectomy); dose-response (fig. 5); pumps replaced after 2 weeks; enzyme inhibitor (17 beta-hydroxysteroid dehydrogenase); cancer (breast carcinoma); animal info (female, Crl: NU/NU, 10-11 wk old); 50% DMSO.

P7880 Lucattelli,M., Fineschi,S., Geppetti,P., Gerard,N.P., Lungarella,G. Neurokinin-1 receptor blockade and murine lung tumorigenesis. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 2006; 174(-6-):674-683. >>> L-733,060; Water, sterile; SC; Mice; 2002; 2 weeks; Controls received mp w/ vehicle; cancer (adenocarcinoma); animal info (Balb/c, C57BL/6, NK1r -/-, bleomycin-induced pulmonary fibrosis, 8-16 wk old); NK-1R antagonist.

P7848 Menu,E., Asosingh,K., Indraccolo,S., De Raeve,H., Van Riet,I., Van Valckenborgh,E., Broek,I.V., Fujii,N., Tamamura,H., Van Camp,B., Vanderkerken,K. The involvement of stromal derived factor 1 alpha in homing and progression of multiple myeloma in the 5TMM model. Haematologica-The Hematology Journal 2006; 91(-5-):605-612. >>> TN14003, 4F-benzoyl-; Saline; SC; Mice; 2004; 3 weeks; Controls received mp w/ vehicle; cancer (myeloma, bone marow); animal info (C57BL/KaLwRij, 8-10 wk. old); CXCR4 inhibitor.

P7840 Choi,J., Credit,K., Henderson,K., Deverkadra,R., He,Z., Wiig,H., Vanpelt,H., Flessner,M.F. Intraperitoneal immunotherapy for metastatic ovarian carcinoma: Resistance of intratumoral collagen to antibody penetration. Clinical Cancer Research 2006; 12(-6-):1906-1912. >>> Immunoglobulin G, donkey anti-rabbit; radio-isotopes; Kreb's solution; bicarbonate; ringer's solution; sodium azide; 125I tracer; IV (jugular); Rat (nude); 2001; 5-7 days; Cancer (metastatic ovarian carcinoma); animal info (RNU-nude, athymic, 150-180g.).

P7807 Jung,F.H., Pasquet,G., Lambert-van der Brempt,C., Lohmann,J.J.M., Warin,N., Renaud,F., Germain,H., De Savi,C., Roberts,N., Johnson,T., Dousson,C., Hill,G.B., Mortlock,A.A., Heron,N., Wilkinson,R.W., Wedge,S.R., Heaton,S.P., Odedra,R., Keen,N.J., Green,S., Brown,E., Thompson,K., Brightwell,S. Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. Journal of Medicinal Chemistry 2006; 49(-3-):955-970. >>> Thiazoloquinazoline, compound 54; Tris buffer; SC; Mice (nude); 2001D; 48 hours; Controls received mp w/ vehicle; half-life (pg. 963) 0.7 hours in mouse plasma; enzyme inhibitor (aurora A/B kinase); cancer (colorectal carcinoma); animal info (Swiss nu/nu, male, 8-10 wk old).

P7800 Palm,D., Lang,K., Niggemann,B., Drell,T.L., Masur,K., Zaenker,K.S., Entschladen,F. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by betablockers. International Journal of Cancer 2006; 118(-11-):2744-2749. >>> Norepinephrine; propranolol; Saline, physiological; ascorbic acid; SC; Mice (nude); 1002; 4 weeks; Controls received mp w/ vehicle; pumps replaced after 2 weeks; half-life (pg. 2745) short, quickly metabolized; cancer (prostate carcinoma); animal info (female, BALB/C nude, athymic, 6 wk. old, 15g.).

P7780 Gu,L.Z., Hu,W.Y., Antic,N., Mehta,R., Turner,J.R., de Lanerolle,P. Inhibiting myosin light chain kinase retards the growth of mammary and prostate cancer cells. European Journal of Cancer 2006; 42(-7-):948-957. >>> ML-7; DMSO; SC; Mice; 2004; 4 weeks; Controls received mp w/ vehicle; no stress (see pg. 952, 955); enzyme inhibitor (myosin light chain kinase); cancer (mammary adenocarcinoma); toxicology; animal info (female, 14-20 wk. old, MMTV-free, C3H/Hen); 50% DMSO.

P7774 Saba,S.R., Garces,A.H., Clark,L.C., Soto,J., Gower,WR Jr, Vesely,D.L. Immunocytochemical localization of atrial natriuretic peptide, vessel dilator, long-acting natriuretic peptide, and kaliuretic peptide in human pancreatic adenocarcinomas. JOURNAL OF HISTOCHEMISTRY&CYTOCHEMISTRY 2005; 53(-8-):989-995. >>> Atrial natriuretic peptide; vessel dilator peptide; kaliuretic peptide; natriuretic peptide, long-acting; Mice (nude); 2004; 4 weeks; Cancer (panceatic adenocarcinoma); peptides; animal info (athymic).

P7768 Damber,J.E., Vallbo,C., Albertsson,P., Lennernaes,B., Norrby,K. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemotherapy and Pharmacology 2006; 58(-3-):354-360. >>> Cyclophosphamide; paclitaxel; Saline; SC; Rat; 2ML1; 10 days; Controls received mp w/ vehicle; cancer (AT-1 adenocarcinoma); animal info (adult, male, copenhagen); "Continuous/metronomic therapy may achieve a more pronounced anti-tumoural effect and significantly diminish the side effects compared with conventional bolus MTD-type chemotherapy." (p. 359).

P7766 Takakura,T., Takimoto,A., Notsu,Y., Yoshida,H., Ito,T., Nagatome,F., Ohno,M., Kobayashi,Y., Yoshioka,T., Inagaki,K., Yagi,S., Hoffman,R.M., Esaki,N. Physicochemical and pharmacokinetic characterization of highly potent recombinant L-methionine -lyase conjugated with polyethylene glycol as an antitumor agent. Cancer Research 2006; 66(-5-):2807-2814. >>> Pyridoxal 5'-phosphate; Sodium phosphate buffer; SC; Mice; 2001; 3 days; Functionality of mp verified by plasma PLP concentrations; cancer; animal info (BALB/c AnNCrj, female, 8-10 wk old, 20-22g); "we believe that DTT-treated PEG-METase should be used together with PLP infusion to minimize the dose&frequency of administration to increase efficacy" (p.2813).

P7764 Pukac,L., Kanakaraj,P., Humphreys,R., Alderson,R., Bloom,M., Sung,C., Riccobene,T., Johnson,R., Fiscella,M., Mahoney,A., Carrell,J., Boyd,E., Yao,X.T., Zhang,L., Zhong,L., von Kerczek,A., Shepard,L., Vaughan,T., Edwards,B., Dobson,C., Salcedo,T., Albert,V. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. British Journal of Cancer 2005; 92(-8-):1430-1441. >>> Fluorouracil, 5-; SC; Mice (nude); 2002; 14 days; Controls received no treatment; cancer (colon); animal info (female, Swiss, athymic, 7-8 wk old, 20g.).

P7755 Aghi,M., Cohen,K.S., Klein,R.J., Scadden,D.T., Chioccra,E.A. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Research 2006; 66(-18-):9054-9064. >>> AMD 3100; SC; Mice; mice (transgenic); 2002; 17 days; Controls received mp w/ PBS; comparison of short-term IV injections vs. mp; cancer (astrocytoma, glioma); animal info (C57BL/6, WT); SDF-1R CXCR4 antagonist.

P7748 Huang,X.L., Brown,C., Ni,W.H., Maynard,E., Rigby,A.C., Oettgen,P. Critical role for the Ets transcription factor ELF-1 in the development of tumor angiogenesis. Blood 2006; 107(-8-):3153-3160. >>> Peptide A1; peptide A1, mutant; PBS; SC; Mice (nude); 10,14 days; Controls received mp w/ vehicle; no stress (see pg. 3157); cancer (B16 melanoma); peptides; animal info (C57BL/6, female); peptide A1 is composed of ETS sequences and a 12-amino acid HIV-TAT protein-transducing membrane peptide.

P7694 Michl,J., Scharf,B., Schmidt,A., Huynh,C. PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. International Journal of Cancer 2006; 119(-7-):1577-1585. >>> PNC-28; PBS, sterile; SC; IP; Mice (nude); 1002; 2 weeks; Controls received mp w/ control peptide; cancer (pancreatic); peptides; animal info (Nu/Nu, 7-8 weeks old, 22-24 g); xenotransplant tumor cells in hindleg or IP; additional mice had IP pumps; "...PNC-28 may be effective in treating cancers especially if delivered directly to the tumor." (p. 1577).

P7673 Dragonas,C., Mueller,A., Maltaris,T., Kraemer,P., Dimmler,A., Jaeger,W., Beckmann,M.W., Dittrich,R. Role of insulin in the progression of ovarian sex cord stromal tumors in rats. Journal of Cancer Research and Clinical Oncology 2005; 131(-11-):751-757. >>> Insulin; SC; Rat; 28, 56, 84 days; Controls received mp w/ saline; replacement therapy (ovariectomy, STZ-induced diabetes); long-term study; pumps replaced every 28 days; no stress (see pg.753); cancer (sex cord stomal); animal info (female, Lewis, 60 days old, 150-210 g).

P7653 Wiig,H., Gyenge,C.C., Tenstad,O. The interstitial distribution of macromolecules in rat tumours is influenced by the negatively charged matrix components. JOURNAL OF PHYSIOLOGY-LONDON 2005; 567(-2-):557-567. >>> Herceptin; immunoglobulin G, 1-; Radio-isotopes; 125I tracer; 131I tracer; IV (jugular); Rat; 2001; 5-7 days; Cancer (mammary); animal info (female, Sprague-Dawley, 208-255 g).

P7612 Gupta,A.K., Cerniglia,G.J., Mick,R., McKenna,W.G., Muschel,R.J. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Research 2005; 65(-18-):8256-8265. >>> Amprenavir; SC; Mice (nude); 1-4, 2-15 days; Controls received mp w/ vehicle; functionality of mp verified by serum drug levels by HPLC; no stress (see pg.826); enzyme inhibitor (HIV protease); cancer (SQ208, head and neck, T24 bladder); animal info (female, Ncr- nu/nu); irradiation.

P7593 Kaufmann,W., Mellert,W., van Ravenzwaay,B., Landsiedel,R., Poole,A. Effects of styrene and its metabolites on different lung compartments of the mouse - cell proliferation and histomorphology. Regulatory Toxicology and Pharmacology 2005; 42(-1-):24-36. >>> Uridine, bromodeoxy-; Saline; SC; Mice; 2001; ; Cancer; toxicology; animal info (female, CD1, 49 days old); labeling of lung cells.

P7549 Munoz-de-Toro,M., Markey,C.M., Wadia,P.R., Luque,E.H., Rubin,B.S., Sonnenschein,C., Soto,A.M. Perinatal exposure to bisphenol-A alters peripubertal mammary gland development in mice. Endocrinology 2005; 146(-9-):4138-4147. >>> Bisphenol A; estradiol; DMSO; SC; Mice (pregnant); 10, 14 days; Controls received mp w/ vehicle; dose-response (fig. 1); cancer (mammary); teratology; animal info (female, CD-1, 9 wk old).

P7444 Green,T., Toghill,A., Lee,R., Waechter,F., Weber,E., Noakes,J. Thiamethoxam induced mouse liver tumors and their relevance to humans - Part 1: Mode of action studies in the mouse. TOXICOLOGICAL SCIENCES 2005; 86(-1-):36-47. >>> Uridine, bromodeoxy-; Sodium bicarbonate; SC; Mice; 1003D; 3 days; Cancer (hepatic); toxicology; animal info (male, 30-43 g); labeling of hepatocytes.

P7441 Green,T., Toghill,A., Lee,R., Waechter,F., Weber,E., Peffer,R., Noakes,J., Robinson,M. Thiamethoxam induced mouse liver tumors and their relevance to humans - Part 2: Species differences in response. TOXICOLOGICAL SCIENCES 2005; 86(-1-):48-55. >>> Uridine, bromodeoxy-; Sodium bicarbonate; SC; Rat; 2ML1; 3 days; Cancer (hepatic); toxicology; animal info (female, 140-160 g).

P7435 Gross,S., Piwnica-Worms,D. Real-time imaging of ligand-induced IKK activation in intact cells and in living mice. NATURE METHODS 2005; 2(-8-):607-614. >>> Luciferin, D-; SC; Mice; 1007D; ; Cancer; bioluminescence imaging (BLI); IVIS; animal info (balb/c, 6 weeks old, male); "By eliminating constraints of intraperitoneal (i.p.) bolus reinjections of substrate, the implanted pump allowed continuous real-time molecular imaging of reporter activity throughout the time course of a multi-day experiment, while simultaneously allowing rapid temporally resolved analysis of short time constants that characterize drug action. This innovation should be generalizable to a variety of other imaging strategies in vivo." P. 613.

P7434 Kawakami,K., Kioi,M., Liu,Q., Kawakami,M., Puri,R.K. Evidence that IL-13R alpha-2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy. Journal of Immunotherapy 2005; 28(-3-):193-202. >>> Interleukin-13-PE38; interleukin-13Ra2, pME18S-; CSF/CNS (intratumoral); Mice (nude); 1003D; 1007D; 7 days; Controls received mp w/ vehicle or antisense IL-13Ra2 plasmid vector; pumps replaced after 3 days; cancer (glioblastoma); cyanoacrylate adhesive; convection enhanced delivery; IL-13Ra2 cDNA encoding plasmid vector; "the upregulated IL-13 Ra2 chain was successfully targeted with a continuous infusion of IL-13 cytotoxin." (p. 199).

P7417 Schmidt,N.O., Przylecki,W., Yang,W., Ziu,M., Teng,Y., Kim,S.U., Black,P.M., Aboody,K.S., Carroll,R.S. Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor. NEOPLASIA 2005; 7(-6-):623-629. >>> Vascular endothelial growth factor, recomb. human; CSF/CNS (parenchyma); Mice; 2004; ; Controls received mp w/ PBS; functionality of mp verified by residual volume; cancer.

P7394 Guarnieri,M., Carson,B.S., Khan,A., Penno,M., Jallo,G.I. Flexible versus rigid catheters for chronic administration of exogenous agents into central nervous system tissues. Journal of Neuroscience Methods 2005; 144(-2-):147-152. >>> Doxorubicin; carboblatin; Dextrose solution; saline; CSF/CNS (parenchyma); Rat; 2001; ; Animal info (F, Fischer, 220 g); Functionality of mp verified by pump examination, post infusion; stability verified by previous studies, 14 days; good methods (p. 148); cancer (glioma); brain tissue distribution; Plastics One cannula used (stainless steel); "replacement of rigid infusion tubes [cannulae] with flexible tubing increases the reliability of local CNS drug infusions. Rigid catheters [cannulae] may allow backflow of the infused drug along the path of the catheters into the subdural space." (P. 147).

P7388 Arcella,A., Carpinelli,G., Battaglia,G., D'Onofrio,M., Santoro,F., Ngomba,R.T., Bruno,V., Casolini,P., Giangaspero,F., Nicoletti,F. Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo. NEURO-ONCOLOGY 2005; 7(-3-):236-245. >>> LY341495; ethylglutamate, alpha-25; Saline; SC; Mice (nude); 1007D; 2004; 7, 28 days; Controls received mp w/ vehicle; cancer (glioma); mGlu 2/3 receptor antagonist; pumps removed prior to MRI.

P7357 Nakagawa,H., Yoshioka,K., Miyahara,E., Fukushima,Y., Tamura,M., Itoh,K. Intrathecal administration of Y-27632, a specific Rho-associated kinase inhibitor, for rat neoplastic meningitis. MOLECULAR CANCER RESEARCH 2005; 3(-8-):425-433. >>> Y-27632; uridine, fluorodeoxy-; PBS; CSF/CNS (Intrathecal, cisterna magna); Rat; 2002; ; Cancer (breast); enzyme inhibitor (rho-associated kinase inhibitor).

P7322 Dings,R.P.M., Williams,B.W., Song,C.W., Griffioen,A.W., Mayo,K.H., Griffin,R.J. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. International Journal of Cancer 2005; 115(-2-):312-319. >>> Anginex; PBS; SC; Mice (nude); 2002; 2004; 2, 4 weeks; Controls received mp w/ vehicle; comparison of IP injections vs. mp; no stress (see pg. 315); half-life (p. 318) 50-90 min. in mice; cancer (ovarian, mammary carcinoma); toxicology; peptides; irradiation 5 Gy once per week or 25 Gy one time tumo-bearing legs; angiogenesis inhibitor; "continuous infusion of anginex in combination with weekly irradiation resulted in tumor regression and impalpable tumors by the end of treatment." P317.

P7321 Aparicio,T., Kotelevets,L., Tsocas,A., Laigneau,J.P., Sobhani,I., Chastre,E., Lehy,T. Leptin stimulates the proliferation of human colon cancer cells in vitro but does not promote the growth of colon cancer xenografts in nude mice or intestinal tumorigenesis in ApcMin/+ mice. Gut 2005; 54(-8-):1136-1145. >>> Leptin, recomb. human; leptin, recomb. murine; Saline, BSA; SC; Mice (nude); mice; 2002; 4, 6 weeks; Controls received mp w/ vehicle; functionality of mp verified by plasma leptin levels; pumps replaced every 2 weeks; cancer (colon, intestinal adenoma); peptides.

P7307 Nakagawa,K., Sasaki,Y., Kato,S., Kubodera,N., Okano,T. 22-oxa-1alpha,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 2005; 26(-6-):1044-1054. >>> Vitamin D3, 1, 25-dihydroxy-; vitamin D3, 22-oxa-la, 25-dihydroxy-; Tween 20; ethanol; SC; Mice; 2ML4; 3 weeks; 10, 18 days; Controls received mp w/ vehicle; dose-response; cancer (lung carcinoma); 10% ethanol; millipore chamber ring; sc dorsal air sac model.

P7287 Guba,M., Koehl,G.E., Neppl,E., Doenecke,A., Steinbauer,M., Schlitt,H.J., Jauch,K.W., Geissler,E.K. Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. TRANSPLANT INTERNATIONAL 2005; 18(-1-):89-94. >>> Rapamycin; DMSO; IP; Mice; 2002; 7-35 days; Controls received mp w/ vehicle; comparison of IP injections vs. mp; cancer (colon adenocarcinoma); "The most effective inhibition of tumor growth occurred in rapamycin-treated mice on the continuous pumping system.;" "Survival data also show the most positive effect with continuous drug delivery." P. 91.

P7283 Ozawa,T., Afzal,J., Lamborn,K.R., Bollen,A.W., Bauer,W.F., Koo,M.S., Kahl,S.B., Deen,D.F. Toxicity, biodistribution, and convection-enhanced delivery of the boronated porphyrin BOPP in the 9L intracerebral rat glioma model. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 2005; 63(-1-):247-252. >>> Porphyrin, boronated; PBS; CSF/CNS (intratumoral); Rat; 2001D; 24 hours; Controls received no treatment; dose-response; comparison of IV injections vs. mp; cancer (brain glioma); toxicology.

P7278 Lobo,E.D., Balthasar,J.P. Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. Journal of Pharmaceutical Sciences 2005; 94(-9-):1957-1964. >>> Methotrexate; IP; Mice; 1003D; 72 hours; Controls received ip bolus saline injection; dose-response (fig. 3); cancer (peritoneal sarcoma); toxicology; mp primed overnight in 37 degrees saline.

P7271 Kashiwagi,S., Izumi,Y., Gohongi,T., Demou,Z.N., Xu,L., Huang,P.L., Buerk,D.G., Munn,L.L., Jain,R.K., Fukumura,D. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. Journal of Clinical Investigation 2005; 115(-7-):1816-1827. >>> L-NMMA; D-NMMA; SC; Mice; mice (SCID); 1002; 8, 21 days; Controls received mp w/ D-NMMA; pumps replaced at day 14; enzyme inhibitor (NO synthase); cancer (melanoma); cardiovascular; eNOS -/- mice; iNOS -/- mice.

P7269 Huss,W.J., Gray,D.R., Greenberg,N.M., Mohler,J.L., Smith,G.J. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Research 2005; 65(-15-):6640-6650. >>> Uridine, bromodeoxy-; Mice (transgenic); 2002; 2 weeks; Cancer (prostate); labeling of the prostate.

P7267 Fluiter,K., Frieden,M., Vreijling,J., Rosenbohm,C., de Wissel,M.B., Christensen,S.M., Koch,T., Orum,H., Baas,F. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. CHEMBIOCHEM 2005; 6(-6-):1104-1109. >>> Oligodeoxynucleotide, antisense; oligodeoxynucleotide, amino-LNA antisense; oligodeoxynucleotide, thio-LNA antisense; oligodeoxynucleotide, LNA antisense; oligodeoxynucleotide, missense; SC; Mice (nude); 1002; 11 days; 48 hours; Controls received mp w/ saline; dose-response (fig. 4); no stress (see pg. 1106); stability verified by incubation in human serum; antisense (H-Ras); cancer (prostate).

P7261 Nakano,K., Todo,T., Zhao,G., Yamaguchi,K., Kuroki,S., Cohen,J.B., Glorioso,J.C., Tanaka,M. Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models. JOURNAL OF GENE MEDICINE 2005; 7(-5-):638-648. >>> Fluorouracil, 5-; IP; Mice (SCID); hamster; 2 weeks; Cancer (gastric, gall bladder carcinoma); pyrimidine synthesis inhibitor.

P7250 Liu,T., Bohlken,A., Kuljaca,S., Lee,M., Nguyen,T., Smith,S., Cheung,B., Norris,M.D., Haber,M., Holloway,A.J., Bowtell,D.D.L., Marshall,G.M. The retinoid anticancer signal: mechanisms of target gene regulation. British Journal of Cancer 2005; 93(-3-):310-318. >>> Retinoic acid, 13-cis-; Ethanol; SC; Mice (transgenic); 1007D; 5 weeks; Controls received mp w/ vehicle; dose-response (fig. 1); no stress (see pg. 312-13); cancer (neuroblastoma).

P7248 Lakka,S.S., Gondi,C.S., Dinh,D.H., Olivero,W.C., Gujrati,M., Rao,V.H., Sioka,C., Rao,J.S. Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas. Journal of Biological Chemistry 2005; 280(-23-):21882-21892. >>> RNA, small interfering; RNA, small interfering, uPAR; RNA, small interfering, MMP-9; CSF/CNS; Mice (nude); 1002; 2 weeks; Controls received mp w/ PBS or empty vector; cancer (glioblastoma); siRNA is within a plasmid vector (pUM vector); antiangiogenesis; gene therapy.

P7233 Haviv,F., Bradley,M.F., Kalvin,D.M., Schneider,A.J., Davidson,D.J., Majest,S.M., McKay,L.M., Haskell,C.J., Bell,R.L., Nguyen,B., Marsh,K.C., Surber,B.W., Uchic,J.T., Ferrero,J., Wang,Y.C., Leal,J., Record,R.D., Hodde,J., Badylak,S.F., Lesniewski,R.R., Henkin,J. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: Design, synthesis, and optimization of pharmacokinetics and biological activities. Journal of Medicinal Chemistry 2005; 48(-8-):2838-2846. >>> ABT-510; Dextrose solution; water; SC; Mice; 2001; 7, 14 days; Controls received mp w/ vehicle; dose-response (fig. 6); half-life (p. 2838); cancer (lung carcinoma); peptides.

P7232 Karam,S.M., John,R., Alpers,D.H., Ponery,A.S. Retinoic acid stimulates the dynamics of mouse gastric epithelial progenitors. Stem Cells 2005; 23(-3-):433-441. >>> Retinoic acid; uridine, bromodeoxy-; SC; Mice; 1, 3, 6 days; Controls received mp w/ vehicle; comparison of SC injections vs. mp; cancer (gastric); multiple pumps per animal (2).

P7197 MacKay,J.A., Deen,D.F., Szoka,FC Jr  Brain Research 2005; 1035(-2-):139-153. >>> Liposomes; FITC-dextran-lysine; Saline; tris buffer; CSF/CNS (caudate putamen); CSF/CNS (intratumoral); Rat; 2001D; 24 hours; Tissue perfusion (intratumoral); comparison of acute CSF/CNS injection vs. mp; half-life (p. 151) 9.9 hours; cancer (glioblastoma); ALZET brian infusion kit 2 used; brain tissue distribution; post op. care (buprenophine).

P7169 Garcia-Castro,J., Martinez-Palacio,J., Lillo,R., Garcia-Sanchez,F., Alemany,R., Madero,L., Bueren,J.A., Ramirez,M. Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors. Cancer Gene Therapy 2005; 12(-4-):341-349. >>> Fluorocytosine, 5-; SC; Mice (SCID); 2004; 4 weeks; Cancer (breast, prostate).

P7166 Cool,J.C., Dyer,J.L., Xian,C.J., Butler,R.N., Geier,M.S., Howarth,G.S. Pre-treatment with insulin-like growth factor-I partially ameliorates 5-fluorouracil-induced intestinal mucositis in rats. GROWTH HORMONE&IGF RESEARCH 2005; 15(-1-):72-82. >>> Insulin-like growth factor I, recomb.human; Acetic acid; SC; Rat; 2002; 7 days; Controls received mp w/ vehicle, no stress (see pg. 75), cancer, peptides, orally administered IGF-1 degrades rapidly in the gastric environment.

P7142 Ruan,W.F., Monaco,M.E., Kleinberg,D.L. Progesterone stimulates mammary gland ductal morphogenesis by synergizing with and enhancing insulin-like growth factor-I action. Endocrinology 2005; 146(-3-):1170-1178. >>> Insulin-like growth factor I, des(1-3); SC; Mice; 1007D; 1002; 5, 28 days; Controls received placebo; replacement therapy (IGF-I [-/-], oophorectomy); pumps replaced at day 14; cancer (breast); endocrinology.

P7136 Bandyopadhyay,A., Wang,L., Loepz-Casillas,F., Mendoza,V., Yeh,I.T., Sun,L.Z. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. PROSTATE 2005; 63(-1-):81-90. >>> Transforming growth factor-B3 receptor, recomb. soluble; PBS; SC; Mice (nude); 2002; 14 days; Controls received mp w/ vehicle; comparison of IP injections vs. mp; no stress (see pg. 84,88); cancer (prostate); multiple pumps per animal (2).

P7135 Benlloch,M., Ortega,A., Ferrer,P., Segarra,R., Obrador,E., Asensi,M., Carretero,J., Estrela,J.M. Acceleration of glutathione efflux and inhibition of gamma-glutamyltranspeptidase sensitize metastatic B16 melanoma cells to endothelium-induced cytotoxicity. Journal of Biological Chemistry 2005; 280(-8-):6950-6959. >>> Acivicin; verapamil; IV; Mice; 2001D; 7 hours; Controls received mp w/ physiological saline; cancer (melanoma).

P7125 Lynch,JJ III, Wade,C.L., Mikusa,J.P., Decker,M.W., Honore,P. ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model. European Journal of Pharmacology 2005; 509(-1-):43-48. >>> Vincristine sulfate; Saline, physiological; IV (external jugular); Rat; 2002; 1-3 weeks; Cancer; mp primed overnight.

P7120 Khan,A., Jallo,G.I, Liu,Y.J, Carson,B.S., Guarnieri,M. Infusion rates and drug distribution in brain tumor models in rats. Journal of Neurosurgery (Pediatrics 1) 2005; 102(--):53-58. >>> Carboplatin; doxorubicin; transferrin-doxorubicin; CSF/CNS; Rat; 2ML1; 2001; 7 days; Cancer (glioma, gliosarcoma); brain tissue distribution; CNS infusion rate study; "...the use of intratumoral infusions significantly increase survival in comparison with bolus injections and conventional systemic treatments." P. 53; flexible tipped cannula components were from Plastics One; in some cases the tubing/cannula were left empty after implantation to allow the tissue to seal before fluid flow.

P7022 Shi,Y.Q., Wu,J.M., Mick,R., Cerniglia,G.J., Cohen-Jonathan,E., Rhim,J.S., Koch,C.J., Bernhard,E.J. Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival. PROSTATE 2005; 62(-1-):69-82. >>> L-744,832; L-788123; DMSO; water, sterile distilled; SC; Mice (nude); 1007D; 3,7 days; Controls received mp w/ vehicle; enzyme inhibitor (farnesyltransferase); cancer (prostate); 50% DMSO; tumor irridiated on day 3.

P6942 El-Salhy,M. Effects of triple therapy with octreotide, galanin and serotonin on a human colon cancer cell line. Oncology Reports 2005; 13(-1-):45-49. >>> Octreotide; galanin; serotonin; Saline; IP; Mice (nude); 1002; 14 days; Controls received mp w/ vehicle; cancer (colon).

P6928 El-Salhy,M. Effects of triple therapy with octreotide, galanin and serotonin on a human colon cancer cell line implanted in mice: comparison between different routes of administration. Histology and Histopathology 2005; 20(-1-):19-25. >>> Octreotide; galanin; serotonin; Saline; SC; IP; Mice (nude); 1002; 14 days; Controls received mp w/ vehicle; comparison of IP injections vs. IP mp; cancer (colon); "continuous i.p infusion appears, however to be the most effective route of administration." (p. 19,25).

P6894 Tejeda,M, Gaal,D., Csuka,O., Keri,G.Y. Growth Inhibitory Effect of the Somatostatin Structural Derivative (TT-232) on Leukemia Models. Anticancer Research 2005; 25(--):325-330. >>> TT-232; Acetic acid; sodium acetate; water; mannitol; IV; SC; Mice; 2002; 14, 28 days; Dose-response (p. 328, fig 1); comparison of IP/SC injections vs. SC/IV mp; pumps replaced at day 14 for 28 day group; stability verified, 37 degrees Celsius for over 3 weeks; cancer (leukemia); TT-232 is a novel somatostatin analog; "The IV infusion for 28 days resulted in 82% growth inhibition." (p. 328); "The infusion of TT-232 by ALZET osmotic minipump resulted in 70-80% tumor growth inhibition and 20% tumor free survival." (p. 329); "…serial injections represent significant stress to the animals…" "To reduce and eliminate the above mentioned problem [stress] we used an ALZET osmotic minipump…" "Infusion from inserted ALZET minipumps maintains a constant drug level, resulting in a well defined, consistent pattern of drug exposure throughout the period of drug administration." "These studies suggest that TT-232 is a potent inhibitor of leukemia tumor in vitro and in vivo and suggest infusion treatment as a beneficial application in clinical practice." (p. 330); oligopeptide; enzyme inhibitor (tyrosine kinase); animal info (CBA/ca, immunosuppressed, female).